

06 Feb 2019 | News

QUOTED. Feb. 6, 2019. Tom Buckland.

by

Scottish device firm Sirakoss has received European clearance for its Osteo³ synthetic bone graft substitute. Tom Buckland, director of Sirakoss, says the company's primary focus is to continue clinical studies to improve surgeon experience with Osteo and prepare for entry into a highly populated space. Read his comments here.

"If commercial opportunities arise as part of these clinical activities, we will evaluate them on a case-by-case basis. Synthetic bone grafting is a crowded field, with many options for surgeons available and many unsubstantiated performance claims being made on the basis of minor technical differences between products. Based on what we believe are significant technical advantages and robust performance data obtained to date, Sirakoss considers that the most effective way to differentiate Osteo³ is on the basis of clinical outcome data. We will now run additional clinical studies to validate our development and strategy." –Tom Buckland, director, Sirakoss

- Find out more: [Scotland's Sirakoss Scores CE Mark For New Bone Graft Technology](#)

[Click here](#) for a free trial of *Medtech Insight*